FDA's New Framework for Psychedelic Drugs

Paper. Davis M, Farchione TR, Fischer BA et al.. The New England Journal of Medicine, 10 Sep 2026.

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 12: Big Pharma and the FDA move

Eli Lilly agreed in July to acquire AtaiBeckley for $2.8 billion. In September, FDA officials set out the agency's updated framework for developing psychedelic drugs in the New England Journal of Medicine, building on its 2023 draft guidance.

How much weight it carries: News and policy, not research findings. (Industry, Policy)

Weekly Science Digest, 5 Sep 2026 to 11 Sep 2026, finding 1: Regulators write for a general medical audience

Four FDA staff, including the psychiatry division director, set out the agency's psychedelic framework in NEJM.

It lands the same week JAMA ran both an Insights piece on psilocybin for depression and a patient-facing explainer, which is its own signal about where the audience now is.

Read the original

—
Node—
Statuslive
Throughput—